Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model

In this letter, we describe our efforts to design HEA BACE-1 inhibitors that are highly permeable coupled with negligible levels of permeability-glycoprotein activity. These efforts culminate in producing 16 which lowers Aβ by 28% and 32% in the cortex and CSF, respectively, in the wild type preclin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2010-11, Vol.20 (21), p.6231-6236
Hauptverfasser: Truong, Anh P., Tóth, Gergley, Probst, Gary D., Sealy, Jennifer M., Bowers, Simeon, Wone, David W.G., Dressen, Darren, Hom, Roy K., Konradi, Andrei W., Sham, Hing L., Wu, Jing, Peterson, Brian T., Ruslim, Lany, Bova, Michael P., Kholodenko, Dora, Motter, Ruth N., Bard, Frédérique, Santiago, Pamela, Ni, Huifang, Chian, David, Soriano, Ferdie, Cole, Tracy, Brigham, Elizabeth F., Wong, Karina, Zmolek, Wes, Goldbach, Erich, Samant, Bhushan, Chen, Linda, Zhang, Hongbing, Nakamura, David F., Quinn, Kevin P., Yednock, Ted A., Sauer, John-Michael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!